ENDRA Life Sciences Inc Surges on Market Strength
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 04 Dec 25
Source: S-1/A
ENDRA Life Sciences Inc saw a significant price increase of 16.84%, breaking above its 5-day SMA amid positive market conditions.
The Nasdaq-100 and S&P 500 indices are both showing slight gains, contributing to a favorable trading environment for stocks like ENDRA.
This upward movement may indicate growing investor confidence in the company, potentially leading to further interest in its upcoming developments.
Analyst Views on NDRA
Wall Street analysts forecast NDRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NDRA is 30.00 USD with a low forecast of 30.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.000
Low
30.00
Averages
30.00
High
30.00
Current: 4.000
Low
30.00
Averages
30.00
High
30.00
About NDRA
ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
